Differential Expression and Potential Value of c-MYC in Non-Invasive and Invasive Mammary Carcinoma

Differential Expression and Potential Value of c-MYC in Non-invasive and Invasive Mammary Carcinoma

Retrospective observational study to evaluate c-MYC expression in non invasive and invasive mammry carcinoma

Study Overview

• Status: Enrolling by invitation
• Conditions: Invasive Breast Cancer
• Intervention / Treatment: Other: no intervention

Detailed Description

To correlate different levels of c-MYC expressions with variable clinical and pathological parameters of mammary carcinoma (such as patients' ages, tumor grading, staging, laterality, focality and nodal metastasis, co-existing in-situ components). This study will be carried out on archived formalin-fixed and paraffin embedded tissue blocks that were belonged to 70 women with breast lumps.

• Study Type: Observational
• Enrollment (Estimated): 70

Contacts and Locations

Study Locations

• Egypt
  • Sohag, Egypt
    • Sohag University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: N/A

• Sampling Method: Probability Sample

Study Population

women with breast lumps administered to oncology center

Description

Inclusion Criteria:

Specimens of Modified Radical Mastectomies from breast carcinoma patients

Exclusion Criteria:

• Cases with insufficient clinical data.

  • Tissue blocks of destroyed or insufficient material, unfit for diagnosis.
  • Cases who received pre-operative chemotherapy.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
non invasive mammary carcinoma; 35 cases with non invasive breast cancer with low and high nuclear grades and co existing microfoci of invasion	Other: no intervention; No intervention
invasive mammary carcinoma; 35 cases of invasive breast cancer undergone MRM and classify them according grading, staging and luminal subtypes	Other: no intervention; No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
role of c-MYC in breast cancer	difference between expression of c-MYC in non invasive and invasive mammary carcinoma	1 year

Collaborators and Investigators

• Sponsor: Marwa Mahmoud Hassan
• Collaborators: Qena Oncology Center
• Investigators: Principal Investigator: Afaf Alnashar, professor, Sohag University

Publications and helpful links

General Publications

• Gao FY, Li XT, Xu K, Wang RT, Guan XX. c-MYC mediates the crosstalk between breast cancer cells and tumor microenvironment. Cell Commun Signal. 2023 Jan 31;21(1):28. doi: 10.1186/s12964-023-01043-1.

Study record dates

Study Major Dates

• Study Start (Actual): March 19, 2024
• Primary Completion (Estimated): April 1, 2025
• Study Completion (Estimated): April 1, 2026

Study Registration Dates

• First Submitted: April 5, 2024
• First Submitted That Met QC Criteria: April 5, 2024
• First Posted (Actual): April 10, 2024

Study Record Updates

• Last Update Posted (Actual): April 10, 2024
• Last Update Submitted That Met QC Criteria: April 5, 2024
• Last Verified: April 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: Soh-Med-24-03-15MS

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No